Hopp til hovedinnholdet

The research group at the Department of Paediatrics and Adolescent Medicine at Stavanger University Hospital consists of 12 members with a doctoral degree: ten doctors, one physiotherapist, and one nurse. In addition, the group includes four PhD candidates. The paediatric research group in Stavanger has an extensive network of collaborators, both locally, nationally, and internationally. Our main research areas are allergology and respiratory diseases, neonatology, immunology, and infectious diseases. However, we have subspecialists covering all fields within paediatrics.

Research sponsored by industry as well as by academic or other institutions are in Stavanger organised in a dedicated unit connected to the department's outpatient clinic. Three experienced nurses hold part-time positions related to research on children, and senior consultant Karen Galta Sørensen holds a part-time position related to NorPedMed. Additionally, we have two senior consultants in professorial positions and three in associate professorial positions at the University of Bergen, engaging in research and teaching medical students.

The department has extensive experience in both researcher-initiated studies and industry-initiated clinical trials, including vaccine trials. Stavanger University Hospital is also the sponsor of the AMIC study (Antibiotics, Microbiology, and Immunology in Children with Chronic Wet Cough). This is an ongoing national multicentre study with two double-blind, randomised, controlled trials (RCTs). A total of 300 children aged 9–36 months with chronic wet cough and a healthy control group of 50 children will be included. We are also involved in other researcher-initiated multicentre studies, particularly within paediatric pulmonary medicine.

Ongoing studies in Stavanger

Viser 8 av 8 rader
REKProsjektStatusSykehusLenker
2014/1633A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical StudyPågår
BergenStavanger
2017/1373A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)Pågår
OsloStavanger
2017/661A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative InfectionsPågår
BergenTrondheimAhusStavanger
2017/660A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years OldPågår
BergenTrondheimAhusStavanger
2019/566A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2)Pågår
OsloStavanger
2017/1863The Norwegian Antibiotics for Pneumonia in Children Study (NAPiC)Pågår
BergenTrondheimStavanger
2018/1495INSTAR: Innovative steroid treatment to reduce asthma development in first-time rhinovirus induced wheezingPågår
BergenTrondheimTromsøAhusStavanger
2014/1930LAMA – Lungefunksjon, AstMa og Allergi. Lungefunksjon, astma og allergi hos 17-åringer etter innleggelse for bronkiolitt i første leveår.Pågår
BergenStavanger

—website under construction—

Contact:

Karen Galta Sørensen

karen.galta.sorensen@sus.no

Publisert: 17. feb. 2026 — Oppdatert: 9. mars 2026